Ga Syfovre denied as non-formulary by Aetna?

Aetna's specific coverage criteria for ga syfovre are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Aetna Denies Syfovre as Non-Formulary — and How to Appeal

Syfovre (pegcetacoplan) may not appear on Aetna's active drug formulary, or may be placed on a tier that requires a formulary exception before coverage applies. Non-formulary denials do not mean the drug is medically inappropriate — they reflect a coverage administrative decision, not a clinical one. Formulary exception processes exist precisely to allow coverage when a formulary alternative is clinically inadequate for a specific patient.

## Why This Denial Is Appealable

Aetna and all ACA-compliant plans must have a formulary exception process. If no formulary alternative is clinically appropriate for your specific diagnosis and presentation, you are entitled to coverage of the non-formulary drug. Geographic atrophy is a distinct retinal condition with a limited approved treatment landscape; if Aetna's formulary does not include an equivalent FDA-approved agent for GA, or if the formulary alternative is contraindicated or has already failed, the exception should be granted.

## Federal Appeal Rights

• ACA §2719 / ERISA §503: Formulary exception denials are subject to the same full-and-fair internal review requirements as any other denial.
• External Review: If the internal formulary exception appeal is denied, an IRO can review whether denial was appropriate. The standard external review window is approximately four months from the final internal denial. Expedited review is available when delay threatens vision or health.
• CMS Formulary Exception Standards: For Medicare Part D plans, CMS requires formulary exceptions when the formulary alternatives are not therapeutically equivalent or have caused or are likely to cause an adverse effect.

## Appeal Timeline

1. Request the non-formulary denial and confirm whether Aetna's formulary lists an alternative agent for geographic atrophy. 2. File a formal formulary exception request with supporting documentation. 3. If denied, file an internal appeal, then escalate to external review.

## Documentation to Gather

• Diagnosis confirmation: Retinal imaging confirming GA secondary to AMD, distinguishing the diagnosis from other forms of AMD that may have different formulary coverage.
• Formulary alternative evaluation: Documentation showing that any formulary-listed alternative for GA is either not FDA-approved for this indication, has been tried and failed, or is otherwise clinically inappropriate for this patient — as documented by your retina specialist.
• Prescriber medical-necessity letter: Your retina specialist should explain why Syfovre specifically is necessary, why formulary alternatives are inadequate, and cite the FDA-approved indication and relevant professional society guidance by organization name.
• Clinical severity documentation: Chart notes establishing the urgency of treatment given GA progression rate and proximity to central vision.

## Criteria-Mapping Strategy

Obtain Aetna's current formulary and Clinical Policy Bulletin for intravitreal GA treatments. Identify whether any formulary alternative exists for the same FDA-approved indication. If no equivalent formulary drug exists for GA specifically, state that plainly in the appeal letter. Map the FDA-approved prescribing information for Syfovre to the patient's diagnosis and confirm on-label use. The formulary exception letter should be structured as: (1) the formulary tier or exclusion, (2) why no listed alternative serves the same indication, and (3) why Syfovre is medically necessary for this specific patient.